Proof of Concept has the meaning set forth in Section 2.3.
Proof of Concept or “POC” means any Service provided by us and/or our Representatives on a trial basis to you.
Proof of Concept means, with respect to any product, the demonstration of the reasonable technical and commercial efficacy and feasibility of such product for its intended application.
Examples of Proof of Concept in a sentence
All capitalized terms used but not defined in these Operating Rules have the meanings assigned in the OpenID Foundation GAIN Proof of Concept Group Participation Agreement to which these Operating Rules are attached.
The Notices File or Proof of Concept (PoC) agreement may limit this evaluation use to an evaluation period.
In case of an Evaluation License, Customer’s Proof of Concept (“PoC”) will be supported by an Exasol PreSales consultant who will be designated by Exasol before the PoC.
Evaluation Service: a demonstration, trial, Proof of Concept, Proof of Value, evaluation or similar service for the XaaS Services and/or related Infrastructure made available from time to time.
The Notices File or Proof of Concept agreement (POC) may limit this evaluation use to an evaluation period.
More Definitions of Proof of Concept
Proof of Concept means an indication of efficacy in patients being studied.
Proof of Concept means the time when a Phase II Clinical Trial for the Product that includes the activities set forth in Schedule 1.74 has been completed.
Proof of Concept means the demonstration of all or substantially all of the properties outlined in the Product Candidate Profile as defined in Schedule 2.1 Research Program, as determined by Merck in its sole discretion.
Proof of Concept means the trial of a Service by a Customer before its official release as a Service by the Supplier;
Proof of Concept means, with regard to Compound or a Licensed Product, clinical trial results which provide meaningful evidence of efficacy and safety in not less than […***…].
Proof of Concept means, with respect to a specified construct, formulation and dose of a specified Licensed Product for the treatment of a specified cancer indication, the demonstration in a Xxxxx 0/Xxxxx 0X xx Xxxxx 0X clinical study of safety and efficacy, sufficient to enable the Licensee to commence multi-center Phase 2 clinical studies without further studies, for such specified construct, formulation and dose of such specified Licensed Product for the treatment of such specified cancer indication. For purposes of the Agreement, “successful completion of a Licensee Phase 2 clinical study” shall mean, with respect to for a specified construct, formulation and dose of a specified Licensed Product in a specified cancer indication, the statistical demonstration in multi-center Phase 2 clinical studies of safety and efficacy, sufficient to enable the Licensee to commence pivotal Phase 3 clinical studies without further studies, for such specified construct, formulation and dose of such specified Licensed Product for the treatment of such specified cancer indication. ***Confidential Treatment Requested CONFIDENTIAL A-294-2011 NIH Patent License Agreement - Exclusive XXXXXXXX X — COMMERCIAL DEVELOPMENT PLAN […***…] ***Confidential Treatment Requested CONFIDENTIAL A-294-2011 NIH Patent License Agreement - Exclusive APPENDIX F — EXAMPLE ROYALTY REPORT Required royalty report information includes: • XXX license reference number (L-XXX-200X/0) • Reporting period • Catalog number and units sold of each Licensed Product (domestic and foreign) • Gross Sales per catalog number per country • Total Gross Sales • Itemized deductions from Gross Sales • Total Net Sales • Earned Royalty Rate and associated calculations • Gross Earned Royalty • Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made • Net Earned Royalty due Example Catalog Number Product Name Country Units Sold Gross Sales (US$) 1 A US 250 62,500 1 A UK 32 16,500 1 A France 25 15,625 2 B US 0 0 3 C US 57 57,125 4 D US 12 1,500 Total Gross Sales 153,250 Less Deductions: […***…] 3,000 […***…] 7,000 Total Net Sales 143,250 Royalty Rate […***…]% Royalty Due […***…] Less Creditable Payments […***…] Net Royalty Due […***…] ***Confidential Treatment Requested CONFIDENTIAL A-294-2011 NIH Patent License Agreement - Exclusive APPENDIX G — ROYALTY PAYMENT OPTIONS The XXX License Number MUST appear on payments, reports and correspondence.